They are also testing inhibitors of JAK2, a molecule that influences ADAR1 activity, for their ability to eliminate cancer stem cells in multiple
myeloma models.
He increased the price target following the introduction of a multiple -
myeloma model to his net present value...
Not exact matches
They also determined that blocking the enzyme reduces multiple
myeloma regeneration in experimental
models derived from patient cancer cells.
To unravel exactly how ADAR1 is connected to disease severity at a molecular level, the researchers transferred multiple
myeloma patient tissue to mice, creating what's known as a xenograft or «humanized»
model.
They also found that silencing the ADAR1 gene in the xenograft
model reduced multiple
myeloma regeneration.
Using their new
model, Jamieson, Crews and team found that two events converge to activate ADAR1 in multiple
myeloma — a genetic abnormality and inflammatory cues from the surrounding bone marrow tissue.
The discovery was made by developing a mouse
model of the disease that enabled researchers to track which of 15 genetic groups — or subclones — of
myeloma cells spread beyond their initial site in the animals» hind legs.
The researchers then tested the capacity of the modified cells to kill human multiple
myeloma cells in laboratory studies and an animal
model.
The researchers grew the modified cells in the lab to increase their numbers and then injected them into an animal
model where they again killed human
myeloma cells.
Small molecule MYC inhibitor conjugated to integrin - targeted nanoparticles extends survival in a mouse
model of disseminated multiple
myeloma.
Modeling multiple
myeloma - bone marrow interactions and response to drugs in a 3D surrogate microenvironment
In our
model disease, multiple
myeloma, we aim to discover molecular mechanisms of the pivotal transition from its premalignant precursor state to the active malignant stage.
Though monoclonal antibodies were a
model product in his 18 years CMO experience, process development was also performed for enzymes, hormones, blood factors, immuno - modulants and vaccines with different expression systems such as hybridoma,
myeloma, CHO, BHK, insect - cell / baculovirus, adherent animal and human cells.